SOLICITATION NOTICE
A -- Assessment of Potential Cocaine Treatment Medications in Non-human Primates
- Notice Date
- 4/11/2013
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211 - MSC 9559, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- N01DA-14-8913
- Point of Contact
- Andrew Hotaling, Phone: 301.443.6677, Kenneth E Goodling, Phone: (301)443-6677
- E-Mail Address
-
hotalingar@mail.nih.gov, kg25d@nih.gov
(hotalingar@mail.nih.gov, kg25d@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Institute on Drug Abuse (NIDA) intends to solicit proposals from qualified organizations (NAICS Code 541712) having in-house capability to perform the following requirements. Under this requirement, NIDA intends to evaluate the efficacy of potential drug abuse treatment medications in non-human primates. Specifically, Rhesus monkeys will be trained in either drug discrimination or self-administration procedures using cocaine or possibly other drugs of abuse. Test compounds will be provided for testing under blinded conditions with information regarding dose, vehicle, and pretreatment time supplied by NIDA. The organization will then evaluate the effects of the test compound to either substitute or antagonize the discriminative stimulus effects of the training drug, or for its effects on the self-administration dose-effect curve of the training compound using standard protocols to be agreed upon in advance. Standardized, detailed reports with graphs will be prepared and submitted promptly to the NIDA program for each compound tested. Approximately eight to fifteen (8-15) compounds per year will be tested using drug discrimination procedures, and another eight to fifteen (8-15) compounds will be tested using self-administration procedures, as specified by NIDA. In order to handle substances under the Controlled Substances Act of 1970, it is mandatory that the successful offeror possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. All offerors must comply with NIH guidelines on the care and use of laboratory animals. We anticipate the award of one cost-reimbursement, level of effort contract for a base period of one year with four one-year options to extend performance. The contract will include additional quantity options. RFP No. N01DA-14-8913 will be available electronically on or about April 26, 2013. You can access the RFP through the FedBizOpps (URL: http://fedbizopps.gov) or through the NIDA website: (URL: http://www.drugabuse.gov/funding/funding-opportunities/nida-requests-contract-proposals-rfps). All information required for the submission of a proposal will be contained in or accessible through the RFP package. Responses to the RFP will be due on or about June 24, 2013. NIDA will consider proposals submitted by any responsible offeror. Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the Contracting Officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice. This advertisement does not commit the Government to award a contract.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/N01DA-14-8913/listing.html)
- Record
- SN03034442-W 20130413/130411235154-b3b69a35cc55fd55a1205ea98929a313 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |